A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus.

Trial Profile

A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Insulin lispro (Primary) ; MK-1092 (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Apr 2018 Type 2 diabetes patients were included in the study.Also planned patient number got changed from 76 to 85 and treatment arm for type 2 diabetes mellitus patients added.
    • 02 Apr 2018 Planned number of patients changed from 76 to 85.
    • 11 Oct 2017 Planned End Date changed from 22 Jun 2018 to 21 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top